Latest News in the pharma Industry
Research & Development
.jpg)
BD completes clinical trial for its wearable injector
11 Feb 2020
The pre-filled, pre-assembled injector is designed to prioritize safety, convenience and usability while delivering high-value drug treatments in the comfort of an in-home environment.
Read more.jpg)
Catalent to manufacture first-in-class mAb targeting solid tumours
11 Feb 2020
ZM008 could have potential benefits for the treatment of prostate cancer.
Read more
New Velesco Pharma clinical manufacturing facility begins operations
5 Feb 2020
The facility will triple the company’s cGMP clinical trial manufacturing capacity.
Read more.jpg)
Inovio and Beijing Advaccine to advance vaccine against Coronavirus
30 Jan 2020
Agreement will facilitate clinical trial translations in China.
Read more.jpg)
Thermo launches next-generation, compressor-free plate sealer
28 Jan 2020
Features new functionalities and capabilities making it versatile for a variety of both manual and automated microplate processing life science applications.
Read more.jpg)
First human trial of monoclonal antibody to prevent malaria opens
28 Jan 2020
If proven safe and effective, mAb CIS43LS might be used prophylactically by tourists, medical workers or military personnel who travel to areas where malaria is common.
Read more.jpg)
Merck invests in biotech development facility in Switzerland
27 Jan 2020
€250 million to be invested during the 2019-2022 period in new facility bridging research and manufacturing.
Read more
Diabetes diagnosis - now a matter of sweat and tears?
21 Jan 2020
No need to draw blood; researchers develop smart technology to diagnose diabetes and treat diabetic retinopathy.
Read more.jpg)
Grey Wolf Therapeutics secures funding for cancer therapies development
21 Jan 2020
The company targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumours for attack and destruction by the immune system.
Read more
BioMarin gets go-ahead to start gene therapy clinical trials
15 Jan 2020
BMN 307 represents a potential third PKU treatment option from BioMarin and its second gene therapy clinical program.
Read more
French regulator agrees to partial resumption of Tellomak trial patient recruitment
14 Jan 2020
The French National Agency for Medicines and Health Product Safety (ANSM) has agreed that Innate Pharma’s Tellomak (lacutamab) Phase II trial can resume recruitment of new patients with relapsed/refractory Sézary syndrome and mycosis fungoides (MF) in ...
Read more
Biogen to acquire novel clinical-stage asset from Pfizer
14 Jan 2020
PF-05251749 complements the company’s pipeline of potential disease-modifying therapies for Alzheimer’s and Parkinson’s diseases.
Read more